Novel N -Methylated Cyclodepsipeptide Prodrugs for Targeted Cancer Therapy

Chunlei Wu,Zhehong Cheng,Danyi Lu,Ke Liu,Yulian Cheng,Pengxin Wang,Yimin Zhou,Meiqing Li,Ximing Shao,Hongchang Li,Wu Su,Lijing Fang
DOI: https://doi.org/10.1021/acs.jmedchem.0c01387
IF: 8.039
2021-01-08
Journal of Medicinal Chemistry
Abstract:Coibamide A (<b>1</b>) is a highly <i>N</i>-methylated cyclodepsipeptide with low nanomolar antiproliferative activities against various cancer cell lines. In previous work, we discovered a simplified analogue, [MeAla3-MeAla6]-coibamide (<b>1a</b>), which exhibited the same inhibitory abilities as coibamide A. Herein, to reduce the whole-body toxicity and improve the solubility of <b>1a</b>, two novel peptide-drug conjugates RGD-SS-CA (<b>2</b>) and RGD-VC-CA (<b>3</b>) were designed, synthesized, and evaluated. Composed of cyclodepsipeptide <b>1a</b>, a tumor-homing RGD motif, and a conditionally labile linker, the conjugates are expected to release <b>1a</b> tracelessly in specific tumor microenvironments. Compared with RGD-VC-CA (<b>3</b>), RGD-SS-CA (<b>2</b>) proved to be superior in in vitro drug release and cytotoxicity tests. Notably, intravenous injection of RGD-SS-CA (<b>2</b>) into mice-bearing human tumor xenografts induced significant tumor growth suppression with negligible toxicity. Therefore, as a novel prodrug of the coibamide A analogue, conjugate <b>2</b> has great potential for further exploration in cancer drug discovery.
chemistry, medicinal
What problem does this paper attempt to address?